Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Codivir
- Development stage
- Phase 2
- Lead developer
- Code Pharma
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
Codivir is a short synthetic 16-amino-acid peptide derived from HIV-1 integrase, originally discovered at the Hebrew University in Israel. It acts as an antiviral agent with demonstrated activity against SARS-CoV-2 and other RNA viruses by suppressing viral replication post-entry into cells.
- Brand names
- Codivir
- Other names
- HIV-1 integrase-derived peptideHIV1 integrase-derived peptideHIV 1 integrase-derived peptide
02
Targets
Integrase allosteric pocket (HIV)
Beyond the preview
Go deeper on Codivir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Codivir.